Navigation Links
Actos Bladder Cancer Lawsuit: Bernstein Liebhard LLP Comments on Outcome of Nation’s Second Actos Lawsuit Trial
Date:9/27/2013

New York, New York (PRWEB) September 27, 2013

The nation’s second trial of an Actos bladder cancer lawsuit (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) has concluded in Maryland state court, Bernstein Liebhard LLP reports. According to court documents, the jury hearing the case found that Takeda Pharmaceuticals failed to provide proper warnings regarding the association between Actos and bladder cancer to a man who died of the disease last year and awarded his family $1.7 million. But the judge presiding over the Actos lawsuit trial tossed out the verdict in accordance with Maryland law because the jury also found that the decedent’s 30-year smoking habit contributed to the development of the disease. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

“This was a difficult case due to the patient’s medical history. But we are encouraged that the jury agreed with the Plaintiffs’ assertion that Takeda failed to adequately warn patients and doctors about the risk of Actos bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of the drug.

Actos Lawsuits
According to court documents, this is the second time a state court jury has found that Takeda failed to provide proper warnings regarding the association between Actos and bladder cancer. In April, a California Superior Court jury reached similar conclusions and awarded more than $6 million to a man who developed the disease after using Actos for four years. However, that verdict was also set aside after the judge in the case ruled that the Plaintiff’s medical expert had failed to establish that Actos was the specific cause of the man’s bladder cancer. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

The litigation surrounding Actos has been growing since June 2011, when the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use increased the risk for bladder cancer. According to a report from Bloomberg.com, Actos was also pulled from the market in France, while German regulator removed it from the country's list of reimbursed drugs, due to the medication’s association with the disease.*

Court records indicate that thousands of Actos bladder cancer lawsuits are now pending in courts throughout the U.S. This includes more than 2,500 claims that have been filed in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. The first trial in that litigation is scheduled to begin in January. (In re: Actos Product Liability Litigation, MDL No. 2299) According to Bloomberg.com, additional state trials will also get underway in Las Vegas and Chicago in the next several months.*

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.

*businessweek.com/news/2013-09-26/takeda-failed-to-properly-warn-about-actos-risks-jury-rules-1

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11172459.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: